AbbVie ABBV announced the submission of regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its drug Skyrizi (risankizumab) for a new indication, moderately to ...

It looks like AbbVie has the trial win it was hoping for to unlock the psoriasis market for its recently-approved psoriasis therapy Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi ...

- Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...

AbbVie has big plans to grow sales for Humira follow-ups Skyrizi and upadacitinib. Early into its Skyrizi launch for psoriasis, the company has offered discounts on its megablockbuster Humira to ...

When AbbVie won FDA approval for its next-generation immunology drugs Skyrizi and Rinvoq in 2019, the company had high hopes that the drugs could fill what threatened to be a gaping hole in the top ...

Skyrizi may lead to mild side effects, including headaches, fatigue, injection site reactions, and upper respiratory infections. Serious side effects, such as an increased risk of infections, may ...

AbbVie, a research-based global biopharmaceutical company, announced it will present data from multiple studies of Rinvoq (upadacitinib), Humira (adalimumab) and ...

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used Stelara in a head-to-head trial.

Skyrizi (risankizumab-rzaa) is a prescription injection used for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Skyrizi is typically given once every 8 to 12 ...